24,194 results match your criteria Am. Heart J.[Journal]


Risk of stroke subsequent to infective endocarditis: A nationwide study.

Am Heart J 2019 Mar 27;212:144-151. Epub 2019 Mar 27.

The Heart Centre, Rigshospitalet, Copenhagen, Denmark.

Background: The aim of the study was to investigate the associated risk of stroke after discharge of infective endocarditis (IE) in patients with stroke during IE admission compared with patients without stroke during IE admission.

Methods: Using Danish nationwide registries, we identified nonsurgically treated patients with IE discharged alive in the period from 1996 to 2016. The study population was grouped into (1) patients with stroke during IE admission and (2) patients without stroke during IE admission. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2019.03.010DOI Listing

Trends and predictors of recurrent acute coronary syndrome hospitalizations and unplanned revascularization after index acute myocardial infarction treated with percutaneous coronary intervention.

Am Heart J 2019 Mar 5;212:134-143. Epub 2019 Mar 5.

Centre of Cardiovascular Research and Education in Therapeutics (CCRE), Monash University, Melbourne, Australia; Department of Cardiovascular Medicine, Alfred Hospital, Melbourne, Australia. Electronic address:

Background: Repeat hospitalizations for recurrent acute coronary syndrome (ACS) or unplanned revascularization after acute myocardial infarction (MI) are common, costly and potentially preventable. We aim to describe 10-year trends and identify independent risk factors of these repeat hospitalizations.

Methods: We analyzed data from 9615 patients from the Melbourne Interventional Group registry (2005-2014) who underwent percutaneous coronary intervention (PCI) for their index MI and survived to discharge. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2019.02.013DOI Listing

Apixaban versus warfarin in evaluation of progression of atherosclerotic and calcified plaques (prospective randomized trial).

Am Heart J 2019 Mar 13;212:129-133. Epub 2019 Mar 13.

Los Angeles Biomedical Research Center, Harbor-UCLA Medical Center, Torrance, CA. Electronic address:

Warfarin has been showed to increase vascular calcification. Apixaban, a direct factor Xa inhibitor, has no interaction with vitamin K and its effect on coronary plaques is unknown. We randomized and compared warfarin and apixaban on progression of coronary atherosclerotic plaques measured by coronary computed tomographic angiography in 66 subjects with non-valvular atrial fibrillation over the period of one-year follow up. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00028703193004
Publisher Site
http://dx.doi.org/10.1016/j.ahj.2019.02.014DOI Listing
March 2019
1 Read

Response to a letter to the Editor by Prof Platonov and Prof Holmqvist.

Authors:
Leif Friberg

Am Heart J 2019 Mar 23. Epub 2019 Mar 23.

Dept. of Clinical Sciences, Karolinska Institutet at Danderyd University Hospital, Stockholm, Sweden. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2019.03.003DOI Listing

Registry data on implantation of ICD is not necessarily reflective of an arrhythmic event.

Am Heart J 2019 Mar 25. Epub 2019 Mar 25.

Department of Cardiology, Clinical Sciences, Lund University, 22185 Lund, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2019.03.008DOI Listing

Prehospital statin use and low-density lipoprotein cholesterol levels at admission in acute coronary syndrome patients with history of myocardial infarction or revascularization: Findings from the Improving Care for Cardiovascular Disease in China (CCC) project.

Am Heart J 2019 Mar 13;212:120-128. Epub 2019 Mar 13.

Department of Epidemiology, Beijing Anzhen Hospital, Capital Medical University, the Key Laboratory of Remodeling-Related Cardiovascular Diseases, Ministry of Education, Beijing Municipal Key Laboratory of Clinical Epidemiology, Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing, China. Electronic address:

Background: Lowering low-density lipoprotein cholesterol (LDL-C) by statins is a key strategy for secondary prevention of acute coronary syndrome (ACS). However, few studies have examined prehospital statin use and admission LDL-C levels in ACS patients with history of myocardial infarction (MI) or revascularization. This study aimed to assess use of prehospital statins and LDL-C levels at admission in ACS patients with history of MI or revascularization. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2019.02.019DOI Listing
March 2019
1 Read
4.463 Impact Factor

In response to letter to the Editor: "Ultrasound guided radial artery catheterization: A superior technique for expert clinicians?"

Am Heart J 2019 Feb 23. Epub 2019 Feb 23.

Wayne State University, Detroit Medical Center Heart Hospital, Detroit, MI, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2019.02.004DOI Listing
February 2019

Performance on management strategies with Class I Recommendation and A Level of Evidence among hospitalized patients with non-ST-segment elevation acute coronary syndrome in China: Findings from the Improving Care for Cardiovascular Disease in China-Acute Coronary Syndrome (CCC-ACS) project.

Am Heart J 2019 Mar 4;212:80-90. Epub 2019 Mar 4.

Department of Epidemiology, Beijing Anzhen Hospital, Capital Medical University, the Key Laboratory of Remodeling-Related Cardiovascular Diseases, Ministry of Education, Beijing Municipal Key Laboratory of Clinical Epidemiology, Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing, China. Electronic address:

Background: This study aimed to examine hospital performance on evidence-based management strategies for non-ST-segment elevation acute coronary syndrome (NSTE-ACS) and variations across hospitals.

Methods: Improving Care for Cardiovascular Disease in China (CCC)-ACS project is an ongoing registry and quality improvement project, with 150 tertiary hospitals recruited across China. We examined hospital performance on nine management strategies (Class I Recommendations with A Level of Evidence) based on established guidelines. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00028703193004
Publisher Site
http://dx.doi.org/10.1016/j.ahj.2019.02.012DOI Listing
March 2019
2 Reads
4.463 Impact Factor

Comparative effectiveness, safety, and costs of rivaroxaban and warfarin among morbidly obese patients with atrial fibrillation.

Am Heart J 2019 Feb 20;212:113-119. Epub 2019 Feb 20.

Department of Medicine, Anticoagulation and Clinical Thrombosis Services, Northwell Health System, The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Manhasset, NY.

Background: There are limited data regarding clinical outcomes and healthcare resource utilization of direct oral anticoagulants (DOACs) in patients with atrial fibrillation (AF) who are morbidly obese (body mass index >40 kg/m or body weight >120 kg).

Methods: Using data from 2 US healthcare claims databases, we identified patients initiating rivaroxaban or warfarin who had ≥1 medical claim with an AF diagnosis, a diagnostic code for morbid obesity (ICD-9: 278.01, V85. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2019.02.001DOI Listing
February 2019
1 Read

Rationale and design of the randomized, controlled Early Valve Replacement Guided by Biomarkers of Left Ventricular Decompensation in Asymptomatic Patients with Severe Aortic Stenosis (EVOLVED) trial.

Am Heart J 2019 Mar 15;212:91-100. Epub 2019 Mar 15.

British Heart Foundation Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, United Kingdom. Electronic address:

Background: The optimal timing of aortic valve replacement in asymptomatic patients with aortic stenosis is uncertain. Replacement fibrosis, as assessed by midwall (nonischemic) late gadolinium enhancement (LGE) on cardiac magnetic resonance (CMR) imaging, is an irreversible marker of left ventricular decompensation in aortic stenosis. Once established, it progresses rapidly and is associated with poor long-term prognosis in a dose-dependent manner. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2019.02.018DOI Listing
March 2019
1 Read

Association of post-discharge specialty outpatient visits with readmissions and mortality in high-risk heart failure patients.

Am Heart J 2019 Mar 21;212:101-112. Epub 2019 Mar 21.

Duke Clinical Research Institute, Durham, NC; Division of Cardiology, Department of Medicine, Duke University School of Medicine, Durham, NC.

Heart failure (HF) outcomes are especially poor in high-risk patients with certain comorbidities including diabetes mellitus (DM), chronic kidney disease (CKD), and chronic obstructive pulmonary disease (COPD). Whether early specialty or primary care provider (PCP) follow-up after HF discharge affects outcomes in high-risk patients is unknown.

Methods: We analyzed patients discharged from a Get With The Guidelines HF-participating hospital from 2007-2012 with linked Medicare claims to investigate the association of medical specialist visit within 14 days of discharge stratified by comorbidity with the primary outcome of 90-day HF readmission. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00028703193006
Publisher Site
http://dx.doi.org/10.1016/j.ahj.2019.03.005DOI Listing
March 2019
5 Reads
4.463 Impact Factor

One database, 2 studies, and a trebling of atherectomy rates.

Am Heart J 2019 Mar 19. Epub 2019 Mar 19.

Cardiology Department, Gosford Hospital, New South Wales, Australia and University of Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2019.03.004DOI Listing

Neck circumference and cardiovascular outcomes: Insights from the Jackson Heart Study.

Am Heart J 2019 Mar 8;212:72-79. Epub 2019 Mar 8.

Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC; Department of Medicine, Duke University School of Medicine, Durham, NC. Electronic address:

Background: Emerging data suggest that neck circumference (NC) is associated with cardiometabolic risk factors. Limited research is available regarding the association between NC and cardiovascular outcomes in African Americans.

Methods: Using data from the Jackson Heart Study, we included participants with recorded NC measurements at baseline (2000-2004). Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00028703193005
Publisher Site
http://dx.doi.org/10.1016/j.ahj.2019.03.001DOI Listing
March 2019
4 Reads
4.463 Impact Factor

Validating the use of registries and claims data to support randomized trials: Rationale and design of the Extending Trial-Based Evaluations of Medical Therapies Using Novel Sources of Data (EXTEND) Study.

Am Heart J 2019 Mar 6;212:64-71. Epub 2019 Mar 6.

Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology; Division of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Boston, MA; Harvard Medical School, Boston, MA; Baim Institute for Clinical Research, Boston, MA. Electronic address:

Background: Randomized controlled trials are the "gold standard" for comparing the safety and efficacy of therapies but may be limited due to high costs, lack of feasibility, and difficulty enrolling "real-world" patient populations. The Extending Trial-Based Evaluations of Medical Therapies Using Novel Sources of Data (EXTEND) Study seeks to evaluate whether data collected within procedural registries and claims databases can reproduce trial results by substituting surrogate non-trial-based variables for exposures and outcomes.

Methods And Results: Patient-level data from 2 clinical trial programs-the Dual Antiplatelet Therapy Study and the United States CoreValve Studies-will be linked to a combination of national registry, administrative claims, and health system data. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2019.02.007DOI Listing
March 2019
1 Read

Myocardial constructive work and cardiac mortality in resynchronization therapy candidates.

Am Heart J 2019 Mar 4;212:53-63. Epub 2019 Mar 4.

Univ Rennes, CHU Rennes, Inserm, LTSI-UMR 1099, F-35000, Rennes, France.

Background: Recent studies have shown that myocardial constructive work (CW) assessed by pressure-strain loops (PSLs) is an independent predictor of a volumetric response to cardiac resynchronization therapy (CRT). The aim of this study was to evaluate the role of CW in predicting the cardiac outcome of heart failure patients undergoing CRT.

Methods: This is a retrospective study including 166 CRT candidates (ejection fraction [EF] ≤35%, QRS duration ≥120 milliseconds). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2019.02.008DOI Listing

Randomized evaluation of ticagrelor monotherapy after 3-month dual-antiplatelet therapy in patients with acute coronary syndrome treated with new-generation sirolimus-eluting stents: TICO trial rationale and design.

Am Heart J 2019 Mar 7;212:45-52. Epub 2019 Mar 7.

Division of Cardiology, Department of Internal Medicine, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea; Cardiovascular Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.

Background: Ticagrelor monotherapy after short-term dual-antiplatelet therapy (DAPT) may optimize ischemic and bleeding risks, particularly for acute coronary syndrome (ACS) patients, because its strategy is less potent than ticagrelor-based DAPT but more potent than aspirin or clopidogrel monotherapy.

Methods: The TICO randomized open-label trial will evaluate whether ticagrelor monotherapy following 3-month DAPT is superior to 12-month ticagrelor-based DAPT in terms of net adverse clinical events (NACE) including efficacy and safety in ACS patients treated with ultrathin bioresorbable polymer sirolimus-eluting stents (BP-SES). Patients undergoing BP-SES implantation for ACS treatment will be randomized in a 1:1 fashion to the (1) ticagrelor monotherapy group after 3-month DAPT; or the (2) 12-month DAPT group. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2019.02.015DOI Listing
March 2019
2 Reads

Randomized controlled trial of influenza vaccine in patients with heart failure to reduce adverse vascular events (IVVE): Rationale and design.

Am Heart J 2019 Mar 11;212:36-44. Epub 2019 Mar 11.

Population Health Research Institute, Hamilton, Ontario, Canada; Department of Medicine, McMaster University, Hamilton, Ontario, Canada.

Background: Influenza is associated with an increase in the risk of cardiac and other vascular events. Observational data and small randomized trials suggest that influenza vaccination may reduce such adverse vascular events.

Research Design And Methods: In a randomized controlled trial patients with heart failure are randomized to receive either inactivated influenza vaccine or placebo annually for 3 years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2019.02.009DOI Listing

Rationale and design of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE).

Am Heart J 2019 Mar 4;212:23-35. Epub 2019 Mar 4.

Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC.

Background: Cardiovascular disease (CVD) is more frequent among people with HIV (PWH) and may relate to traditional and nontraditional factors, including inflammation and immune activation. A critical need exists to develop effective strategies to prevent CVD in this population.

Methods: The Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) (A5332) is a prospective, randomized, placebo-controlled trial of a statin strategy for the primary prevention of major adverse cardiovascular events (MACE) in PWH with low to moderate traditional risk. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2018.12.016DOI Listing
March 2019
1 Read
4.463 Impact Factor

Relationship of stroke and bleeding risk profiles to efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after percutaneous coronary intervention: An ancillary analysis from the RE-DUAL PCI trial.

Am Heart J 2019 Mar 1;212:13-22. Epub 2019 Mar 1.

Brigham and Women's Hospital Heart and Vascular Center and Harvard Medical School, Boston, MA.

Background: In the RE-DUAL PCI trial of patients with atrial fibrillation (AF) who underwent percutaneous coronary intervention (PCI), dabigatran dual therapy (110 or 150 mg bid, plus clopidogrel or ticagrelor) reduced International Society on Thrombosis and Haemostasis bleeding events compared with warfarin triple therapy, with noninferiority in overall thromboembolic events. This analysis assessed outcomes in relation to patient bleeding and stroke risk profiles, based on the modified HAS-BLED and CHADS-VASc scores.

Methods: The primary endpoint, major bleeding event (MBE) or clinically relevant nonmajor bleeding event (CRNMBE), was compared across study arms in patients categorized by modified HAS-BLED score 0-2 or ≥3. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2019.02.006DOI Listing
March 2019
5 Reads

Rationale and design of the Mechanistic Substudy of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE): Effects of pitavastatin on coronary artery disease and inflammatory biomarkers.

Am Heart J 2019 Mar 4;212:1-12. Epub 2019 Mar 4.

MGH Program in Nutritional Metabolism and Harvard Medical School, Boston, MA.

Background: People with HIV (PWH) have increased cardiovascular events, inflammation, and high-risk coronary atherosclerosis. Statin therapy has been shown to lower the risk of cardiovascular disease (CVD) in the general population, but whether this results from reductions in coronary atherosclerosis and is mediated by decreased inflammation remains unknown.

Methods: REPRIEVE is a randomized, placebo-controlled trial of pitavastatin calcium (4 mg/day) vs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2019.02.011DOI Listing
March 2019
1 Read

Association of frailty and cognitive impairment with benefits of oral anticoagulation in patients with atrial fibrillation.

Am Heart J 2019 May 30;211:77-89. Epub 2019 Jan 30.

Department of Cardiology, Mayo Clinic, Rochester, MN.

Background: The incidence of cognitive impairment and frailty increase with age and may impact both therapy and outcomes in atrial fibrillation (AF).

Methods: We examined the prevalence of clinically recognized cognitive impairment and frailty (as defined by the American Geriatric Society Criteria) in the Outcomes Registry for Better Informed Care in AF (ORBIT AF) and associated adjusted outcomes via multivariable Cox regression. The interaction between cognitive impairment and frailty and oral anticoagulation (OAC) in determining outcomes was examined. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2019.01.005DOI Listing
May 2019
3 Reads
4.463 Impact Factor

Adverse events in patients with high platelet reactivity following successful chronic total occlusion PCI: The Assessment of Dual AntiPlatelet Therapy with Drug-Eluting Stents (ADAPT-DES) study.

Am Heart J 2019 May 20;211:68-76. Epub 2019 Feb 20.

New York-Presbyterian Hospital/Columbia University Medical Center, New York, NY; Cardiovascular Research Foundation, New York, NY.

Background: Chronic total occlusion (CTO) percutaneous coronary intervention (PCI) typically requires a greater number of stents and longer stent length than non-CTO PCI, placing these patients at greater risk for adverse ischemic events. We sought to determine whether the association between high platelet reactivity (HPR) and the risk of ischemic events is stronger after CTO than non-CTO PCI.

Methods: Patients undergoing successful PCI in the multicenter ADAPT-DES study were stratified according to whether they underwent PCI of a CTO. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2019.02.002DOI Listing
May 2019
1 Read

Mineralocorticoid receptor antagonist pre-treatment and early post-treatment to minimize reperfusion injury after ST-elevation myocardial infarction: The MINIMIZE STEMI trial.

Am Heart J 2019 May 20;211:60-67. Epub 2019 Feb 20.

Hatter Cardiovascular Institute, London, United Kingdom; Barts Heart Centre, St Bartholomew's Hospital, London, United Kingdom; The National Institute of Health Research University College London Hospitals Biomedical Research Centre, London, United Kingdom; National Heart Research Institute Singapore, National Heart Centre Singapore, Singapore; Cardiovascular and Metabolic Disorders Program, Duke-National University of Singapore, Singapore; Yong Loo Lin School of Medicine, National University Singapore, Singapore; Tecnologico de Monterrey, Centro de Biotecnologia-FEMSA, Nuevo Leon, Mexico. Electronic address:

Background: Mineralocorticoid receptor antagonist (MRA) therapy has been shown to prevent adverse left ventricular (LV) remodeling in ST-segment elevation myocardial infarction (STEMI) patients with heart failure. Whether initiating MRA therapy prior to primary percutaneous coronary intervention (PPCI) accrues additional benefit of reducing myocardial infarct size and preventing adverse LV remodeling is not known. We aimed to investigate whether MRA therapy initiated prior to reperfusion reduces myocardial infarct (MI) size and prevents adverse LV remodeling in STEMI patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2019.02.005DOI Listing
May 2019
2 Reads

Peripheral blood metabolite profiles associated with new onset atrial fibrillation.

Am Heart J 2019 May 14;211:54-59. Epub 2019 Feb 14.

Duke Clinical Research Institute, Duke University Medical Center, Durham, NC; Duke Clinical & Translational Science Institute, Duke University Medical Center, Durham, NC. Electronic address:

Background: Peripheral blood metabolite profiles have yielded mechanistic insights into various cardiovascular disease states. We hypothesized that peripheral blood metabolite profiles would be associated with new onset atrial fibrillation (AF).

Methods And Results: The study population comprised 1892 patients without AF at baseline, who, as part the MURDOCK Cardiovascular Disease Study molecular profiling cohort (n = 2023), had previously had determination of levels of 69 metabolites from frozen, fasting plasma specimens obtained during coronary angiography. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2019.01.010DOI Listing

Rationale and design for AMPLATZER Amulet Left Atrial Appendage Occluder IDE randomized controlled trial (Amulet IDE Trial).

Am Heart J 2019 May 21;211:45-53. Epub 2018 Dec 21.

St. Francis Hospital, Roslyn, NY.

The Amulet IDE Trial is an ongoing, prospective, randomized, multi-national trial, designed to evaluate the safety and effectiveness of the AMPLATZER Amulet Left Atrial Appendage Occluder for stroke prevention in comparison to the WATCHMAN Left Atrial Appendage Closure Device in patients with non-valvular atrial fibrillation. METHODS: Non-valvular atrial fibrillation patients at high risk of stroke (CHADS score ≥2 or a CHADS-VASc score of ≥3) who are suitable candidates for left atrial appendage occlusion (LAAO) will be fully informed and requested to participate in the trial. A total of 1878 patients at up to 150 sites worldwide will be randomized in a 1:1 ratio between the AMPLATZER Amulet device (investigational) and the Boston Scientific WATCHMAN device (control). Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00028703183035
Publisher Site
http://dx.doi.org/10.1016/j.ahj.2018.12.010DOI Listing
May 2019
9 Reads
4.463 Impact Factor

Performance of atherosclerotic cardiovascular risk prediction models in a rural Northern Chinese population: Results from the Fangshan Cohort Study.

Am Heart J 2019 May 5;211:34-44. Epub 2019 Feb 5.

Department of Epidemiology and Biostatistics, Peking University Health Science Center, Beijing, China. Electronic address:

Background: Performance of Pooled Cohort Equations (PCEs) for atherosclerotic cardiovascular disease (ASCVD) risks varied across populations. Whether the recently developed Prediction for ASCVD Risk in China (China-PAR) model could accurately predict cardiovascular risks in real practice remains unclear.

Methods: A population-based cohort study in rural Beijing in the "stroke belt" in North China was used to externally validate PCE and China-PAR models for 5-year ASCVD risk prediction. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2019.01.009DOI Listing

Utilizing mobile technologies to improve physical activity and medication adherence in patients with heart failure and diabetes mellitus: Rationale and design of the TARGET-HF-DM Trial.

Am Heart J 2019 May 31;211:22-33. Epub 2019 Jan 31.

Duke Clinical Research Institute, Durham, NC. Electronic address:

Heart failure (HF) and diabetes mellitus (DM) are major public health issues that place significant burden on patients and health care systems. Patients with both HF and DM are at higher risk of adverse cardiovascular and HF outcomes than those with either disease in isolation. Different antihyperglycemic medications (even within the same medication class) have conflicting results of benefit or harm in patients with established and incident HF. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2019.01.007DOI Listing
May 2019
2 Reads

Outcomes after STEMI in old multimorbid patients with complex health needs and the effect of invasive management.

Am Heart J 2019 May 1;211:11-21. Epub 2019 Feb 1.

Department of Cardiology and Cardiovascular Research Centre, Landspitali University Hospital, Reykjavik, Iceland; School of Health Sciences, University of Iceland, Reykjavik, Iceland.

Background: The aim of this study was to assess one-year outcomes of invasive and non-invasive strategies in ST-elevation myocardial infarction (STEMI) among multimorbid older people with complex health needs.

Methods: We included patients, registered between 2006 and 2013 in the SWEDEHEART registry, who were 70 years old or older with STEMI, had multimorbidity and complex health needs and were discharged alive. The one-year outcomes of patients who underwent invasive strategy (examined with coronary angiography ≤14 days) were compared to those who did not. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2019.01.008DOI Listing
May 2019
1 Read

Long-term outcomes for heart failure patients with and without diabetes: From the Get With The Guidelines-Heart Failure Registry.

Am Heart J 2019 May 27;211:1-10. Epub 2019 Jan 27.

Ahmanson-UCLA Cardiomyopathy Center, University of California, Los Angeles Medical Center, Los Angeles, CA. Electronic address:

Background: Diabetes mellitus is an increasingly prevalent condition among heart failure (HF) patients. The long-term morbidity and mortality among patients with and without diabetes with HF with reduced (HFrEF), borderline (HFbEF), and preserved ejection fraction (HFpEF) are not well described.

Methods: Using the Get With The Guidelines (GWTG)-HF Registry linked to Centers for Medicare & Medicaid Services claims data, we evaluated differences between HF patients with and without diabetes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2019.01.006DOI Listing
May 2019
1 Read
4.463 Impact Factor

Association between the timing of surgery for complicated, left-sided infective endocarditis and survival.

Am Heart J 2019 Apr 17;210:108-116. Epub 2019 Jan 17.

Duke University Medical Center, Durham, NC.

Background: In patients with active infective endocarditis (IE), the relationship between timing of surgery and survival is uncertain. The objective was to evaluate clinical characteristics associated with timing of surgery and the association between surgical timing and 6-month survival in complicated, left-sided IE.

Methods: In a prospective, multicenter, observational registry (The International Collaboration on Endocarditis-PLUS, registry from 2008 to 2012), clinical factors associated with timing of surgery during the index hospitalization were determined among 485 adult patients with definite, complicated, left-sided IE who underwent cardiac surgery during their index hospitalization. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2019.01.004DOI Listing
April 2019
3 Reads

A randomized, double-blind, placebo-controlled trial to assess the efficAcy and safety of Trimetazidine in patients with angina pectoris having been treated by percutaneous coronary intervention (ATPCI study): Rationale, design, and baseline characteristics.

Am Heart J 2019 Apr 15;210:98-107. Epub 2019 Jan 15.

Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Européen Georges Pompidou (HEGP), Department of Cardiology, Paris, France; Université Paris-Descartes, Paris, France; INSERM U-970, Paris, France.

Background: About 30% of angina patients have persisting symptoms despite successful revascularization and antianginal therapy. Moreover, in stable patients, percutaneous coronary intervention (PCI) does not improve survival as compared with medical therapy alone. Trimetazidine, an antianginal agent devoid of hemodynamic effect, may help reducing symptoms and improving outcomes after PCI. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00028703193000
Publisher Site
http://dx.doi.org/10.1016/j.ahj.2018.12.015DOI Listing
April 2019
4 Reads

Trends in cardiorespiratory fitness: The evolution of exercise treadmill testing at a single Academic Medical Center from 1970 to 2012.

Am Heart J 2019 Apr 16;210:88-97. Epub 2019 Jan 16.

Duke Clinical Research Institute, Duke Medicine, Durham, NC; Division of Cardiology, Department of Medicine, Duke University School of Medicine, Durham, NC; Duke Molecular Physiology Institute, Durham, NC.

Objective: To identify temporal trends in the use of exercise treadmill testing (ETT) and cardiorespiratory fitness (CRF) estimated by ETT in metabolic equivalents (METs).

Patients And Methods: We compiled an ETT database of all available treadmill tests-including those with concomitant stress echocardiography and nuclear perfusion imaging studies-performed at Duke University Hospital from January 1, 1970- December 31, 2012. Six different ramp protocols were used in these combined modalities. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2019.01.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6441626PMC
April 2019
3 Reads

Radial versus femoral vascular access in ST-elevation myocardial infarction: Are the results of femoral operators unfairly represented in observational research?

Am Heart J 2019 Apr 16;210:81-87. Epub 2019 Jan 16.

Institute of Cardiovascular Medicine and Science, Liverpool Heart and Chest Hospital, Liverpool.

Background: Recent randomized controlled trials comparing femoral and radial access in primary percutaneous coronary intervention (PPCI) have shown conflicting results regarding the incidence of major adverse cardiovascular events (MACE) and major bleeding.

Methods: Using data from the HEAT-PPCI trial, we compared the primary efficacy (all-cause mortality, stroke, new myocardial infarction or unplanned repeat revascularization) and safety (major bleeding BARC 3-5) outcomes at 28 days, by final access site used (radial or femoral) and by default operator type. We then assessed outcomes in femoral cases performed by both operator types. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2018.12.009DOI Listing
April 2019
3 Reads
4.463 Impact Factor

Rationale and design of a multicenter randomized trial to compare the graft patency between no-touch vein harvesting technique and conventional approach in coronary artery bypass graft surgery.

Am Heart J 2019 Apr 6;210:75-80. Epub 2018 Dec 6.

Department of Surgery, National Center for Cardiovascular Disease, China & Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. Electronic address:

Background: Vein graft failure is a crucial challenge in coronary artery bypass graft (CABG) surgery. Previous studies have suggested a patency benefit of the No-Touch vein harvesting technique, but only with small sample sizes.

Materials And Methods: This study is a prospective, multicenter randomized clinical trial with a large sample size, aiming to investigate the efficacy of the No-Touch technique compared with the conventional approach. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2018.11.011DOI Listing
April 2019
2 Reads

Knowledge of myocardial infarction symptoms and perceptions of self-risk in Tanzania.

Am Heart J 2019 Apr 15;210:69-74. Epub 2019 Jan 15.

Department of Medicine, Duke University Medical Center, 2301 Erwin Rd, Durham, NC.

Background: Little is known about community knowledge of myocardial infarction symptoms and perceptions of self-risk in sub-Saharan Africa.

Methods: A community survey was conducted in northern Tanzania, where the prevalence of cardiovascular risk factors is high. Households were selected randomly in a population-weighted fashion and surveys were administered to self-identified household healthcare decision-makers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2019.01.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6453561PMC
April 2019
1 Read

Early initiation of extracorporeal life support in refractory out-of-hospital cardiac arrest: Design and rationale of the INCEPTION trial.

Am Heart J 2019 Apr 14;210:58-68. Epub 2018 Dec 14.

Department of Intensive Care, Maastricht University Medical Center, Maastricht, The Netherlands; NUTRIM, School for Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, The Netherlands; Department of Surgery, Maastricht University Medical Center, Maastricht, The Netherlands.

Return of spontaneous circulation occurs in less than 10% of patients with cardiac arrest undergoing cardiopulmonary resuscitation (CPR) for more than 15 minutes. Studies suggest that extracorporeal life support during cardiopulmonary resuscitation (ECPR) improves survival rate in these patients. These studies, however, are hampered by their non-randomized, observational design and are mostly single-center. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2018.12.008DOI Listing
April 2019
4 Reads

C-reactive protein and prognosis after percutaneous coronary intervention and bypass graft surgery for left main coronary artery disease: Analysis from the EXCEL trial.

Am Heart J 2019 Apr 11;210:49-57. Epub 2019 Jan 11.

Clinical Trials Center, Cardiovascular Research Foundation, New York, NY; NewYork-Presbyterian Hospital/Columbia University Medical Center, New York, NY. Electronic address:

Background: The prognostic impact of high-sensitivity C-reactive protein (CRP) levels in patients with left main coronary artery disease (LMCAD) treated with percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) is unknown. We sought to determine the effect of elevated baseline CRP levels on the 3-year outcomes after LMCAD revascularization and to examine whether CRP influenced the relative outcomes of PCI versus CABG.

Methods: In the EXCEL trial, patients with LMCAD and Synergy between PCI with Taxus and Cardiac Surgery (SYNTAX) scores ≤32 were randomized to PCI versus CABG. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2018.12.013DOI Listing
April 2019
10 Reads
4.463 Impact Factor

Heart failure and adverse heart failure outcomes among persons living with HIV in a US tertiary medical center.

Am Heart J 2019 Apr 11;210:39-48. Epub 2019 Jan 11.

Cardiac MR PET CT Program, Department of Radiology and Division of Cardiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA. Electronic address:

Background: Persons living with HIV (PLHIV) have an increased risk of heart failure (HF). However, little is known about outcomes among PLHIV with HF. The study aim was to compare HF outcomes among PLHIV with HF versus individuals without HIV with HF. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2019.01.002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6441629PMC
April 2019
2 Reads
4.463 Impact Factor

Rationale and design of the SI! Program for health promotion in elementary students aged 6 to 11 years: A cluster randomized trial.

Am Heart J 2019 Apr 8;210:9-17. Epub 2019 Jan 8.

Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain; The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY. Electronic address:

Unhealthy habits in children are increasing at an alarming rate. The school provides a promising setting for effective preventive strategies to improve children's lifestyle behaviors. The SI! Program is a multilevel multicomponent school-based educational intervention aimed at all stages of compulsory education in Spain. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2018.12.011DOI Listing
April 2019
4 Reads

Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants.

Am Heart J 2019 Apr 10;210:18-28. Epub 2019 Jan 10.

Department of Epidemiology, Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Hirschengraben 84, Zurich, Switzerland. Electronic address:

The current guidelines of statins for primary cardiovascular disease (CVD) prevention were based on results from systematic reviews and meta-analyses that suffer from limitations.

Methods: We searched in PubMed for existing systematic reviews and individual open-label or double-blinded randomized controlled trials that compared a statin with a placebo or another, which were published in English until January 01, 2018. We performed a random-effect pairwise meta-analysis of all statins as a class and network meta-analysis for the specific statins on different benefit and harm outcomes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2018.12.007DOI Listing
April 2019
5 Reads

Radial versus femoral approach for saphenous vein grafts angiography and interventions.

Am Heart J 2019 Apr 12;210:1-8. Epub 2019 Jan 12.

London Health Sciences Centre, London, Ontario, Canada; Keele Cardiovascular Research Group, Centre for Prognosis Research, Institute for Primary Care and Health Sciences, Keele University, Stoke-on-Trent, United Kingdom; Department of Epidemiology and Biostatistics, Schulich School of Medicine & Dentistry, Western University, London, Ontario, Canada. Electronic address:

Background: Coronary angiography and intervention to saphenous venous grafts (SVGs) remain challenging. This study aimed to investigate the feasibility and safety of the radial approach compared to femoral access in a large cohort of patients undergoing SVG angiography and intervention.

Methods: Data from 1,481 patients from Canada, United States, and Spain who underwent procedures between 2010 and 2016 were collected. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2018.11.014DOI Listing
April 2019
1 Read

Design and rationale of the Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Standard DAPT Regimen (MASTER DAPT) Study.

Am Heart J 2019 Mar 22;209:97-105. Epub 2018 Nov 22.

Department of Cardiology, Bern University Hospital, Bern, Switzerland. Electronic address:

Background: The optimal duration of antiplatelet therapy in high-bleeding risk (HBR) patients with coronary artery disease treated with newer-generation drug-eluting bioresorbable polymer-coated stents remains unclear.

Design: MASTER DAPT (clinicaltrial.govNCT03023020) is an investigator-initiated, open-label, multicenter, randomized controlled trial comparing an abbreviated versus a standard duration of antiplatelet therapy after bioresorbable polymer-coated Ultimaster (TANSEI) sirolimus-eluting stent implantation in approximately 4,300 HBR patients recruited from ≥100 interventional cardiology centers globally. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00028703183030
Publisher Site
http://dx.doi.org/10.1016/j.ahj.2018.10.009DOI Listing
March 2019
13 Reads

Development of a cardiac inherited disease service and clinical registry: A 15-year perspective.

Am Heart J 2019 Mar 19;209:126-130. Epub 2018 Dec 19.

Greenlane Paediatric and Congenital Cardiac Services, Starship Children's Hospital, Auckland, New Zealand. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2018.11.013DOI Listing

Design and rationale of a randomized noninferiority trial to evaluate the SurVeil drug-coated balloon in subjects with stenotic lesions of the femoropopliteal artery - the TRANSCEND study.

Am Heart J 2019 Mar 28;209:88-96. Epub 2018 Dec 28.

The Baim Institute for Clinical Research, Boston, MA; The Brigham and Women's Hospital, Boston, MA.

Background: Drug-coated balloons (DCBs), developed to reduce restenosis after percutaneous intervention in peripheral arterial disease (PAD), have been shown to be safe and efficacious, particularly in treating PAD affecting the femoropopliteal segment. The SurVeil DCB uses an excipient intended to optimize both the uniformity and transfer of paclitaxel to the vessel wall, allowing for efficient drug loading and lower systemic exposure than currently available DCBs, Heretofore, clinical outcomes have not previously been compared to other DCBs.

Study Design And Objectives: This prospective, multicenter, international, randomized, single-blind, trial will compare 1:1 the SurVeil DCB with the IN. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00028703183036
Publisher Site
http://dx.doi.org/10.1016/j.ahj.2018.12.012DOI Listing
March 2019
7 Reads

Differences in statin utilization and lipid lowering by race, ethnicity, and HIV status in a real-world cohort of persons with human immunodeficiency virus and uninfected persons.

Am Heart J 2019 Mar 20;209:79-87. Epub 2018 Dec 20.

Northwestern University Feinberg School of Medicine, Chicago, IL. Electronic address:

Background: Risks for cardiovascular diseases, including myocardial infarction and stroke, are elevated in people with HIV infection (PWH). However, no trials of statin utilization with clinical cardiovascular disease (CVD) end points have been completed in PWH, and there are sparse real-world data regarding statin use and lipid-lowering effectiveness. We therefore used a unique cohort of PWH and uninfected controls to evaluate (1) differences in statin types used for PWH versus uninfected persons; (2) lipid lowering achieved by statin use for PWH versus uninfected persons; and (3) racial and ethnic disparities in appropriate statin use among PWH and uninfected persons. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2018.11.012DOI Listing
March 2019
1 Read

Vitamin D with calcium supplementation and risk of atrial fibrillation in postmenopausal women.

Am Heart J 2019 Mar 13;209:68-78. Epub 2018 Dec 13.

Division of Cardiovascular Medicine, Department of Medicine, Stanford University, Stanford, CA. Electronic address:

Background: Atrial fibrillation (AF) is the most common arrhythmia in adults. Although vitamin D deficiency is associated with AF risk factors, retrospective studies of association with AF have shown mixed results. We sought to determine the efficacy of calcium and vitamin D (CaD) supplementation for AF prevention in a randomized trial. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2018.12.006DOI Listing
March 2019
1 Read

Comparison of the change in heart failure readmission and mortality rates between hospitals subject to hospital readmission reduction program penalties and critical access hospitals.

Am Heart J 2019 Mar 7;209:63-67. Epub 2018 Dec 7.

Stanford University School of Medicine, Stanford, CA; Veterans Affairs Palo Alto Health Care System, Palo Alto, CA.

Background: The Hospital Readmission Reduction Program (HRRP), announced in 2010, penalizes hospitals with high readmissions for multiple conditions including heart failure.

Methods: We compared heart failure readmission and mortality rates in hospitals exposed to HRRP financial penalties with critical access hospitals (CAHs) not subject to the penalty between 2005 and 2016 using 3-year moving averages from Hospital Compare.

Results: After HRRP introduction, CAHs experienced a 0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2018.12.002DOI Listing